

GOODWIN & WELLS ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY

INTELLECTUAL PROPERTY RIGHTS FOR BREAKTHROUGH ORAL RADIOPROTECTOR

New York, NY --- November 25, 2013

Goodwin & Wells, a biotechnology company focused on developing a portfolio of products formulated to reduce the side effects of radiation exposure, today announced an exclusive licensing agreement with Albert Einstein College of Medicine of Yeshiva University for rights to a patent application relating to the oral administration of melanin for protection against radiation. Goodwin & Wells co-founders, Dr. Arturo Casadevall, M.D., Ph.D., and Ekaterina Dadachova, Ph.D., are named as inventors on the patent application. Successful development and commercialization of the invention could substantially reduce gastrointestinal tract related side effects commonly associated with radiation therapies and medical imaging.

Millions of people a year are exposed to significant amounts of radiation as a part of medical imaging and cancer therapies. Goodwin & Wells is leveraging advancements based on this discovery to develop a portfolio of orally administered products formulated to reduce the extremely debilitating side effects of radiation exposure.

"We are excited to take this next step in partnership with Albert Einstein College of Medicine to bring natural products to patients who can most benefit," said Goodwin & Wells founder and Chief Executive Officer, Paul Tumpowsky. "Our goal is to bring this product and others into the marketplace and improve patient quality of life."

Edward Burns, M.D., Executive Dean of Albert Einstein College of Medicine of Yeshiva University, stated, "We are proud to be collaborating with Goodwin & Wells on this endeavor as we seek to move basic scientific discoveries from bench to bedside as therapeutic interventions to enhance health."

"There is tremendous need for simple, non-toxic agents to protect against radiation and this product is an example of a natural solution for the prevention of radiation sickness that can be used in many therapeutic situations," added Dr. Arturo Casadevall.

Dr. Ekaterina Dadachova added "It is gratifying that the results of the serendipitous inquiry into the interaction of melanin with ionizing radiation may be translated into clinically useful products."

ABOUT GOODWIN & WELLS

Goodwin & Wells, a New York-based biotechnology company, is focused on the development of a portfolio of products formulated for oral use designed to reduce the side effects of radiation associated with the gastrointestinal tract - including nausea, internal burning, and loss of appetite, as well as other symptoms associated with GI radiation syndrome.

ABOUT ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY

Albert Einstein College of Medicine of Yeshiva University in Bronx, NY is a premier, research-intensive medical school dedicated to innovative biomedical investigation and the development of ethical and compassionate physicians and scientists.

CONTACT

Paul Tumpowsky, CEO
Goodwin & Wells
paul@goodwinandwells.com
212.999.6200